- Poster presentation
- Open Access
In silico docking studies for designing potent anti-diabetic derivatives of swertiamarin with enzyme HMG COA reductase
© Bhatt et al; licensee BioMed Central Ltd. 2014
Published: 21 January 2014
Swertiamarin, a secoiridoid glycoside is found in abundant quantity in Enicostemma Littorale herb and is the main constituent responsible for anti-diabetic and anti-obesity effects of the plant extract. It has been reported to act on various enzymes and transcription factors involved in glucose and lipid metabolism, including inhibition of the enzyme HMG-CoA reductase which might be one of the mechanisms responsible for the antihyperlipidaemic activity. However, owing to its high water solubility, it has a low plasma half life; and thus we have designed its derivatives which bind more efficiently with HMG CoA Reductase.
Materials and methods
Docking was carried out using software namely Autodock and Vina, and repeated at least thrice to minimise the error and to confirm the repeatability. The obtained results were scored and sorted on the basis of the binding energy. The Autodock docking was only done on the inhibitor ligands that were taken from the crystal structure to cross check the results of Molecular Operated Environment [MOE] in terms of binding orientation. Attempts were also made to evaluate in silico toxicity and identification of other possible targets for the lead molecule swertiamarin.
We could design 23 compounds which were docked into the active site of the crystal structure of HMGR. The interactions of these molecules were compared with the presently known inhibitors such as atorvastatin and simvastatin. Based on the results of docking score a number of potent ligands for the enzyme HMGR as compared to swertiamarin were established. It was observed that the designed molecules SWL18, SWL21, SWL22 showed better docking score (-60.74; -61.43 and –55.68 respectively) and tight binding in pockets. Docking score of these molecules were very similar to the atorvastatin and simvastatin.
SWL18, SWL21, SWL22 possess tight binding with HMGR as compared to swertiamarin, which suggest that these molecules could have better HMGR inhibition.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.